AstraZeneca – MARKET LIVE: Nifty eyeing 14,100 at open; BEML, RIL, AstraZeneca in focus
Besides this, DGCI also approved phase 3 clinical trials of Ahmedabad-based Cadila Healthcare’s ZyCov-D, paving the way for a timely roll-out of another indigenous Covid-19 vaccine.
SGX Nifty was up 117 points at 14,133, indicating a strong start for the domestic indices back home.
Global cues
Asian share markets got the new year off to a solid start on expectations central banks will keep money super cheap while the rollout of coronavirus vaccines helps slowly revive the global economy.
MSCI’s broadest index of Asia-Pacific shares outside Japan edged up 0.1%, a whisker from a record high. Japan’s Nikkei rose 0.4% to reach peaks not seen since August 1990 while E-Mini futures for the S&P 500 were flat after touching a new all-time high in early trade.
(With inputs from Reuters)